Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol

Trial Details

NCT ID
NCT07152041
Phase
PHASE3
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • olverembatinib
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Must meet all items below:
  • Age older than 1 month to younger 18 years.
  • Newly diagnosed Philadelphia chromosome-positive or BCR::ABL1-positive B-ALL.
  • Written informed consent of the parents or other legally authorized guardian of the patient according to local law and regulations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →